AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Wed 14 May 25, 06:29 PMSolid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business
Tue 13 May 25, 10:16 AMSupernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Thu 08 May 25, 11:02 AMSupernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
Tue 06 May 25, 11:00 PMSupernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
Tue 06 May 25, 09:30 PMSupernus Announces First Quarter 2025 Financial Results
Tue 06 May 25, 08:08 PMSupernus Pharmaceuticals Earnings: What To Look For From SUPN
Mon 05 May 25, 07:11 AM3 Stocks Under $50 That Concern Us
Tue 29 Apr 25, 01:05 PMWhat Makes Supernus (SUPN) a New Buy Stock
Mon 28 Apr 25, 04:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 60.74M | 73.17M | 168.65M | 147.49M | 140.18M |
| Minority interest | - | - | - | - | - |
| Net income | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M |
| Selling general administrative | 109.43M | 105.05M | 65.92M | 158.43M | 159.89M |
| Selling and marketing expenses | 267.79M | 199.71M | 134.75M | - | - |
| Gross profit | 580.02M | 504.71M | 467.94M | 376.10M | 393.54M |
| Reconciled depreciation | 82.63M | 32.59M | 18.14M | 6.66M | 7.06M |
| Ebit | 67.30M | 86.03M | 173.70M | 148.57M | 151.22M |
| Ebitda | 149.93M | 120.06M | 210.00M | 170.19M | 158.29M |
| Depreciation and amortization | 82.63M | 34.03M | 36.31M | 21.62M | 7.06M |
| Non operating income net other | 14.62M | -12.85400M | -5.05000M | -1.08400M | 9.57M |
| Operating income | 67.30M | 86.03M | 173.70M | 148.57M | 144.44M |
| Other operating expenses | 621.62M | 500.28M | 344.80M | 244.18M | 264.45M |
| Interest expense | 7.07M | 23.42M | 23.75M | 22.71M | 18.11M |
| Tax provision | 0.03M | 19.75M | 41.70M | 34.43M | 29.18M |
| Interest income | 21.69M | 10.57M | 18.70M | 21.62M | 13.84M |
| Net interest income | 14.62M | -12.85400M | -5.05000M | -1.08400M | -4.26800M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.03M | 19.75M | 41.70M | 34.43M | 29.18M |
| Total revenue | 667.24M | 579.77M | 520.40M | 392.75M | 408.90M |
| Total operating expenses | 534.40M | 425.21M | 292.34M | 227.52M | 249.10M |
| Cost of revenue | 87.22M | 75.06M | 52.46M | 16.66M | 15.36M |
| Total other income expense net | -6.56000M | -12.85400M | -5.05000M | -1.08400M | -4.26800M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M |
| Net income applicable to common shares | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1408.98M | 1702.51M | 1689.15M | 1504.10M | 1160.28M |
| Intangible assets | 599.89M | 702.46M | 784.69M | 442.25M | 24.84M |
| Earning assets | - | - | - | - | - |
| Other current assets | 16.68M | 15.78M | 27.02M | 18.68M | 11.61M |
| Total liab | 487.46M | 816.30M | 873.30M | 759.24M | 564.85M |
| Total stockholder equity | 921.52M | 886.20M | 815.85M | 744.86M | 595.43M |
| Deferred long term liab | - | 49.81M | 85.36M | 35.22M | - |
| Other current liab | 279.90M | 139.84M | 64.97M | 39.98M | 3.24M |
| Common stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.05M |
| Capital stock | 0.06M | 0.05M | 0.05M | 0.05M | 0.05M |
| Retained earnings | 482.56M | 481.25M | 379.92M | 326.50M | 199.55M |
| Other liab | - | 92.35M | 137.37M | 123.81M | 28.66M |
| Good will | 117.02M | 117.02M | 117.52M | 77.91M | 24.84M |
| Other assets | - | 10.90M | 13.87M | 259.71M | 32.68M |
| Cash | 75.05M | 93.12M | 203.43M | 288.64M | 181.38M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 290.20M | 687.96M | 315.38M | 245.11M | 160.59M |
| Current deferred revenue | 0.00000M | 49.81M | 126.25M | 122.43M | 144.38M |
| Net debt | -33.52700M | 344.85M | 217.12M | 101.69M | 194.23M |
| Short term debt | 8.33M | 401.97M | 6.48M | 3.76M | 2.83M |
| Short long term debt | - | 401.97M | - | - | - |
| Short long term debt total | 41.53M | 437.97M | 420.55M | 390.33M | 375.61M |
| Other stockholder equity | 439.49M | 408.12M | 434.34M | 409.33M | 388.41M |
| Property plant equipment | - | 44.08M | 52.32M | 37.82M | 17.07M |
| Total current assets | 493.11M | 734.15M | 601.59M | 630.42M | 472.64M |
| Long term investments | 16.62M | 93.90M | 119.17M | 350.36M | 591.77M |
| Net tangible assets | - | 66.72M | -86.35800M | 302.61M | 570.59M |
| Short term investments | 179.82M | 368.21M | 136.25M | 133.89M | 165.69M |
| Net receivables | 144.16M | 165.50M | 148.93M | 140.88M | 87.33M |
| Long term debt | - | - | 379.25M | 361.75M | 345.17M |
| Inventory | 77.41M | 91.54M | 85.96M | 48.33M | 26.63M |
| Accounts payable | 1.96M | 96.34M | 117.68M | 78.93M | 10.14M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.59300M | -3.21000M | 1.54M | 8.97M | 7.42M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.05M | 0.05M | 0.05M | 0.05M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 481.25M | 379.92M | 326.50M | 199.55M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8.51M | -10.00300M | -36.12300M | 8.03M | 0.61M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 915.86M | 968.36M | 1087.56M | 873.68M | 687.64M |
| Capital lease obligations | 41.53M | 36.00M | 47.77M | 28.58M | 33.27M |
| Long term debt total | - | - | 379.25M | 361.75M | 345.17M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -216.25100M | 218.94M | 267.53M | -156.53700M | -411.82700M |
| Change to liabilities | -19.16300M | 18.18M | 8.27M | -11.87100M | 4.12M |
| Total cashflows from investing activities | -216.66300M | -81.91300M | -34.69900M | -157.92400M | -413.48000M |
| Net borrowings | - | -138.31500M | -0.80200M | -0.80200M | 392.06M |
| Total cash from financing activities | -10.47700M | -130.42000M | 3.56M | 3.93M | 376.44M |
| Change to operating activities | 29.14M | -3.89600M | -0.05600M | -11.19700M | 47.62M |
| Net income | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M |
| Change in cash | -110.31400M | -85.20600M | 107.26M | -10.86700M | 91.94M |
| Begin period cash flow | 203.43M | 288.64M | 181.38M | 192.25M | 100.30M |
| End period cash flow | 93.12M | 203.43M | 288.64M | 181.38M | 192.25M |
| Total cash from operating activities | 116.83M | 127.13M | 138.40M | 143.13M | 128.99M |
| Issuance of capital stock | 12.42M | 7.09M | 4.36M | 3.93M | 11.58M |
| Depreciation | 85.54M | 32.59M | 18.14M | 6.66M | 7.06M |
| Other cashflows from investing activities | -0.41200M | -300.84900M | -298.78200M | 1.35M | -0.80900M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -17.85800M | -14.58000M | -10.12400M | -0.96900M | -9.35500M |
| Change to account receivables | -16.36600M | 3.87M | -34.60700M | 15.75M | -35.85600M |
| Sale purchase of stock | 12.42M | 7.09M | 4.36M | 3.93M | 77.27M |
| Other cashflows from financing activities | -22.90000M | 0.80M | -34.69900M | -157.92400M | 364.86M |
| Change to netincome | -10.51600M | 19.62M | 16.13M | 9.01M | 7.13M |
| Capital expenditures | 0.41M | 2.04M | 3.45M | 2.74M | 0.84M |
| Change receivables | -16.36600M | 3.87M | -34.60700M | 15.75M | -35.85600M |
| Cash flows other operating | 29.13M | -3.89600M | -0.05600M | 0.12M | 34.71M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -110.31400M | -85.20600M | 107.26M | -10.86700M | 91.94M |
| Change in working capital | -24.24300M | 3.57M | -36.51500M | 0.61M | -4.73400M |
| Stock based compensation | 17.57M | 17.91M | 16.56M | 14.85M | 11.29M |
| Other non cash items | 3.57M | 24.62M | 12.69M | 13.79M | 8.54M |
| Free cash flow | 116.41M | 125.08M | 134.95M | 140.39M | 128.14M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals Inc |
-0.5 0.92% | 53.67 | - | 20.16 | 2.72 | 1.80 | 2.37 | 16.01 |
| ZTS Zoetis Inc |
-1.87 1.53% | 120.49 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.56 2.23% | 25.64 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.64 2.02% | 128.01 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.14 0.77% | 18.21 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
9715 Key West Avenue, Rockville, MD, United States, 20850
| Name | Title | Year Born |
|---|---|---|
| Mr. Jack A. Khattar | Founder, Pres, CEO, Sec. & Director | 1961 |
| Mr. Timothy C. Dec | Sr. VP & CFO | 1959 |
| Dr. Padmanabh P. Bhatt | Chief Scientific Officer & Sr. VP of Intellectual Property | 1957 |
| Ms. Tami T. Martin | Sr. VP of Regulatory Affairs | 1955 |
| Dr. Jonathan Rubin | Sr. VP of R&D and Chief Medical Officer | 1961 |
| Mr. Kevin T. Anderson | Compliance Officer | 1962 |
| Dr. Todd Horich M.B.A., Ph.D. | Sr. VP of Marketing & Market Access | NA |
| Mr. Taylor Raiford | Sr. VP of Sales | NA |
| Dr. Bryan A. Roecklein Ph.D. | Sr. VP of Corp. Devel. | NA |
| Mr. Frank Mottola | Sr. VP of Quality, GMP Operations & Information Technology | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...